REPL

Replimune Group, Inc.

Latest Form 4:Sale$148KbyXynos Konstantinos (Chief Medical Officer) · filed Aug 12, 2026

Replimune Group, Inc. (REPL) has 24 SEC Form 4 filings (24 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 12, 2026.

The most active filer is Chief Commercial Officer Sarchi Christopher with 3 filings. Insiders have net sold $1.5M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Sushil Patel
  • Employees:465
  • HQ:Woburn, MA, US
  • IPO:2018-07-20

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.5M

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$1.3B

latest known value

Source
Sale$148KAug 12SEC ↗
Sale$510KAug 12SEC ↗
Sale$99KAug 12SEC ↗
Sale$148KAug 12SEC ↗
Sale$111KJun 4SEC ↗
Xynos KonstantinosFirst filing
Sale$71KMay 20SEC ↗
Hill Emily LuisaFirst filing
Sale$40KMay 20SEC ↗
Sale$44KMay 20SEC ↗
Sale$90KMay 20SEC ↗
Patel SushilFirst filing
Sale$190KMay 20SEC ↗
Sale$40KMay 20SEC ↗
Sarchi ChristopherFirst filing
Sale$52KApr 6SEC ↗

Related companies

Replimune Group, Inc. is in the Healthcare sector.